Author Archives: admin


Harvard scientist worries we’re ‘reverting to a pre-Enlightenment form of thinking’ – SCNow

George Q. Daley, the new head of Harvard Medical School, knows what it's like when presidential politics collides with science. Daley was a leading stem cell scientist back in 2001 when President George W. Bush suddenly barred federal funding for research on new embryonic stem cells - a gesture to Republican antiabortion backers that, many believe, put a chill on one of the most cutting-edge areas of biology.

The move turned many scientists, unexpectedly, into activists. The diplomatic Daley helped Harvard create an institute in 2004 to work around the federal funding restrictions; California bucked the Bush administration by devoting its own state funds to the research. President Barack Obama eventually reversed the executive order in 2009, allowing federal funds to be used; today, embryonic stem cell based therapies are being tested in clinical trials, and studying them has helped unleash a wave of new medical insights.

As of Jan. 1, Daley occupies one of the highest-profile jobs in American medicine, a de facto spokesman both for research and medical practice. And he arrives at a moment when the entire field is nervous about what the Trump administration has in store. The White House seems not only indifferent to research, but also actively hostile to some strains of science; the future of the Affordable Care Act is uncertain at best. Drug prices, immigration and the national research budget - all issues crucial to the medical field - are all up for debate. By nature a scientist, accustomed to gathering evidence before opining about solutions, Daley says he thinks his experiences working in a field that was marginalized by politicians may provide some useful lessons for navigating what he called a "cacophony of confusion and alternative facts."

Daley spoke to The Washington Post about his hopes and concerns as he takes the helm at Harvard Medical School - around the same time as President Trump. This interview has been edited for clarity and length.

Q. Right now, there's uneasiness in the scientific and medical communities over how evidence and research will be treated, ranging from vaccines to climate change. Having lived through a time when your work was directly politicized and targeted, what are your thoughts about how to approach a situation like that?

A. I think that the lessons that I learned in the early challenges and policy debates around embryonic stem cells have a lot to teach us for how to advocate forcefully in today's world. We have to, as scientists, stick to our message, which is that science and evidence is the way to make informed decisions - whether those decisions are about advancing human health and wellness, or about advancing the environment and maintaining not only healthy air quality, but reducing risks to catastrophic climate change. These are all fundamentally, at some level, challenges and risks to human health.

If I had one worry, as we see the cacophony of confusion and alternative facts, it's that we're reverting to a pre-Enlightenment form of thinking, which will take us back to the days of blood-letting and faith-healing. And this is wrong. This is not the way to advance health and wellness for the greatest number, not a way to face our challenges. We are facing some of the greatest global challenges today - not just with global warming, but with threats to emerging pathogens, whether it's Ebola or Zika. And if we start to question the nature and value of things like vaccines in human health, how are we going to be able to confront the challenges of new pathogens?

Q. Do you think that this is something that's already happening, or is it a future worry?

A. The storm clouds are on the horizon. If I just speak to one issue that has a very direct effect on our community: Our biomedical research enterprise, as well as our clinicians draw on the best and brightest, from not only the United States, but around the globe. We are a magnet, we're seen as the beacon of the best, cutting-edge research and the most effective and impactful clinical training and health care delivery. I've met with students from Iran and Syria who are here studying and about to graduate. And they're worried that their parents are not going to be able to come see them receive their PhD or their MD. We're worried about the pipeline - not only of trainees who keep us at the cutting edge, but patients. Our health care centers are magnets for patients from all over the world, and in many cases from the Middle East, and it stands in the way of our mission.

Q. The immigration policy of the Trump administration is evolving as we speak, but it sounds like you're worried about the message that recent actions send.

A. Our concern is that there is a megaphone that screams across the globe. Over the couple-hundred-year history of our country, it has been emblazoned on the Statue of Liberty: Give us your tired, your poor. We are a welcome beacon to immigrants from all across the globe; that's been the message that has built our country. And now the recent message that has been sent is giving pause to those folks in other parts of the world, making them think twice about whether this is a welcoming community for them. I've already heard that some of our applicants to post-doctoral positions or training programs in our graduate schools are starting to be diverted to programs in Europe that are saying, "Hey, what can we do to take advantage of the talent pool that might not be going to the United States." That is chilling to me.

Q. What are your thoughts on the plans to repeal the Affordable Care Act and what should come next?

A. We now have, in Massachusetts, 96 percent of people covered, and I do think that's created a sense in our medical students and our residents and our trainees, and even up to our faculty, that universal access [to health care] is a human right. I remember in my times in the hospital, there was something absolutely wonderful about the fact the homeless person coming off the street with a heart attack got the same intense, compassionate care as the Berkeley professor who had a heart event at Logan Airport - and that's an actual case that took place when I was in training. There's probably no other experience in my time as at trainee at the Harvard hospitals that made me feel more proud about the mission of Harvard medicine. I think that's an aspiration - there was an attempt by the Obama administration to capture that as an aspiration, as the noblest calling of medicine, and I think that anything that is put in it place has to attempt to meet those same aspirations.

Q. Stem cell science has come under political attack in the past, and Vice President Pence has said he opposes embryonic stem cell research. Are you worried about the future of your field?

A. I always felt very strongly and passionately, as an advocate for stem cell research of all kinds. To be able to use the new technology and biology of regenerative medicine to serve the relief of suffering and the treatment of disease, I just think is a very noble calling. I've always argued that we need to exploit every possible advantage in the fight against disease. I would continue to advocate for research on all sorts of stem cells. And if there is an attempt to restrict the research in the future, I will be out there again, speaking from the scientific and medical perspective to justify this work.

Carolyn Johnson is a reporter covering the business of health. She previously wrote about science at The Boston Globe

More:
Harvard scientist worries we're 'reverting to a pre-Enlightenment form of thinking' - SCNow

Stem cells fiercely abide by innate developmental timing, study shows – Science Daily

Stem cells fiercely abide by innate developmental timing, study shows
Science Daily
Developmental clocks are of high importance to regenerative medicine, since many cell types take long periods to grow to maturity, limiting their usefulness to human therapies. The regenerative biology team at the Morgridge Institute for Research, led ...

and more »

Go here to read the rest:
Stem cells fiercely abide by innate developmental timing, study shows - Science Daily

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM … – EconoTimes

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.

SHANGHAI, China and CUPERTINO, Calif., Feb. 27, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG)(CBMG or the Company), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $2.29 million to support pre-clinical studies of AlloJoinTM, CBMGs Off-the-Shelf Allogeneic Human Adipose-derived Mesenchymal Stem Cells for the treatment of Knee Osteoarthritis in the United States.

While CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM in Knee Osteoarthritis (KOA), this latest announcement represents CBMGs initial entrance into the United States for its off-the-shelf allogeneic stem cell candidate AlloJoinTM.

The $2.29 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. After the award, CIRM will be a more active partner with its recipients to further increase the likelihood of clinical success and help advance a pre-clinical applicants research along a funding pipeline towards clinical trials. CBMGs KOA pre-clinical program is considered late-stage, and therefore it meets CIRM 2.0s intent to accelerate support for clinical stage development for identified candidates of stem cell treatments that demonstrate scientific excellence.

"We are deeply appreciative to CIRM for their support and validation of the therapeutic potential of our KOA therapy, said Tony (Bizuo) Liu, Chief Executive Officer of CBMG. We thank Dr. C. Thomas Vangsness, Jr., in the Department of Orthopaedic Surgery at the Keck School of Medicine of the University of Southern California and Dr. Qing Liu-Michael at the Broad Center for Regenerative Medicine and Stem Cell Research at USC, who helped significantly with the grant application process. The CIRM grant is the first step in bringing our allogeneic human adipose-derived mesenchymal stem cell treatment for knee osteoarthritis (AlloJoinTM) to the U.S. market.

Our AlloJoinTM program has previously undergone extensive manufacturing development and pre-clinical studies and is undergoing a Phase I clinical trial in China. In order to demonstrate comparability with cell banks previously produced in China for our U.S. IND filing, we are addressing the pre-clinical answers required for the FDA. With the funds provided by CIRM, we will replicate and validate the manufacturing process and control system at the cGMP facility located at Childrens Hospital Los Angeles to support the filing of an IND with the FDA. The outcome of this grant will enable us to have qualified final cell products ready to use in a Phase I clinical trial with Dr. Vangsness as the Principal Investigator and the Keck School of Medicine of USC as a trial site. Dr. Vangsness is familiar with both stem cell biology and KOA, and has led the only randomized double-blind human clinical study to investigate expanded allogeneic mesenchymal stem cells to date. Our endeavor in the U.S. market will further strengthen our commercialization pipeline.

CBMG recently announced promising interim 3-month safety data from its Phase I clinical trial in China for AlloJoinTM, its off-the-shelf allogeneic stem cell therapy for KOA. The trial is on schedule to be completed by the third quarter of 2017.

About CIRM

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and to act with a sense of urgency commensurate with that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.

With $3 billion in funding and over 280 active stem cell programs in our portfolio, CIRM is the world's largest institution dedicated to helping people by bringing the future of medicine closer to reality.

For more information, please visit http://www.cirm.ca.gov.

About Knee Osteoarthritis

According to the Foundation for the National Institutes of Health, there are 27 million Americans with Osteoarthritis (OA), and symptomatic Knee Osteoarthritis (KOA) occurs in 13% of persons aged 60 and older. The International Journal of Rheumatic Diseases, 2011 reports that approximately 57 million people in China suffer from KOA. Currently no treatment exists that can effectively preserve knee joint cartilage or slow the progression of KOA. Current common drug-based methods of management, including anti-inflammatory medications (NSAIDs), only relieve symptoms and carry the risk of side effects. Patients with KOA suffer from compromised mobility, leading to sedentary lifestyles; doubling the risk of cardiovascular diseases, diabetes, and obesity; and increasing the risk of all causes of mortality, colon cancer, high blood pressure, osteoporosis, lipid disorders, depression and anxiety. According to the Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257), 53% of patients with KOA will eventually become disabled.

About Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMGs scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit http://www.cellbiomedgroup.com.

Forward-looking Statements

This press release contains forward-looking statementsincluding descriptions of plans, strategies, trends, specific activities, investments and other non-historical factsas defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMGs reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," "continue" or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

See the original post here:
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM ... - EconoTimes

Gene therapy to fight a blood cancer succeeds in major study – Columbus Ledger-Enquirer


Columbus Ledger-Enquirer
Gene therapy to fight a blood cancer succeeds in major study
Columbus Ledger-Enquirer
In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. The experimental gene therapy ...
Kite Pharma (KITE) Reports Positive Topline Data on Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in ...StreetInsider.com
Kite Pharma Inc (KITE) Research Coverage Started at Wells Fargo & CoSports Perspectives

all 22 news articles »

More:
Gene therapy to fight a blood cancer succeeds in major study - Columbus Ledger-Enquirer

Stem cell therapy can help in treating diabetic heart disease – Business Standard

Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on "Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease" at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge. Patients suffering from the condition have to undergo lifelong treatment and medications. "In this backdrop, advancements in stem cell therapy assume significance," he said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Original post:
Stem cell therapy can help in treating diabetic heart disease - Business Standard

All eyes on Garrett Richards, in hopes stem cells stave off Tommy … – USA TODAY

With MLB spring training underway, there's plenty to talk about. USA TODAY Sports

Garrett Richards is aiming to pitch through a ligament tear via stem cell therapy and other recovery methods.(Photo: Rick Scuteri, USA TODAY Sports)

TEMPE, Ariz. Garrett Richards first thought when he found out about his torn elbow ligament last May was to schedule Tommy John surgery as soon as possible.

It made sense, considering the ligament-replacement procedure has become the standard fix for such injuries. Plus, the Los Angeles Angels ace was familiar with the operating room, having undergone surgery for a ruptured patellar tendon he sustained on Aug. 20, 2014, toward the end of a breakout season.

Richards knew how to handle the seemingly interminable months of rehab, and he wanted to get the clock started on his return.

But a conversation with Angels head physical therapist Bernard Li convinced Richards to consider other alternatives, and in mid-May he tried a relatively novel treatment in which stem cells taken from bone marrow in his pelvis were injected into the damaged area.

Richards did not pitch again the rest of the year except for a stint in the instructional league, but he has been back on the mound throwing bullpen sessions since the first day of the Angels camp and reported no problems.

This weekend, Richards anticipates pitching in a game for the first time since May 1, when his aching elbow forced him from a start after just four innings.

Its nice to know Ill be able to start the season this year and kind of pick up where I left off, Richards said.

A couple of lockers away, fellow starter Andrew Heaney had a different tale to tell.

Royals know the deal: Win now, or say goodbye

One burning question facing every AL team

Tim Tebow reports to Mets camp ready for 'hardest thing in sports'

The promising left-hander also went down with a torn ulnar collateral ligament early in the season, after making only one start. Their ailments were the two biggest blows to an Angels rotation that was decimated by injuries, dooming the club to a 74-88 record and a fourth-place finish in the AL West.

Heaney also tried stem cell therapy, two weeks before Richards, both under the supervision of team doctor Steve Yoon. Heaneys ligament didnt heal, though, and after experiencing discomfort throwing following his rehab, he had Tommy John surgery July 1. He has been ruled out for the 2017 season.

They tell you its 50-50. It either works or it doesnt, Heaney said of the stem cell procedure. Obviously, me and Garrett are pretty much the proof of that rule.

Even with less-favorable odds than reconstructive surgery, which has an 80% success rate for returning to action and 67% for pitching 10 games or more, stem cell therapy is gaining acceptance as an option for pitchers with partial UCL tears. The recovery time is shorter 3-5 months instead of 12-18 and the treatment less invasive.

There are limitations. Biological approaches based on stem cells or platelet-rich plasma (PRP) wont repair a complete tear of the ligament. The location of the injury and its extent factor into the chances of success. And players whose ligament doesnt recover, then have to undergo surgery, extend their window of time for returning to action.

Even then, the idea of healing without going under the knife is becoming increasingly appealing. New York Yankees ace Masahiro Tanaka treated the small tear in his elbow ligament with PRP and rehabilitation in 2014, sitting out 10 weeks but coming back to pitch in late September.

Hes 26-11 with a 3.26 ERA over the last two seasons, raising the profile of PRP a procedure in which the players own blood is used to promote healing of the injury as a non-surgical alternative.

Now Richards looms as the test case for stem cell treatment to fix partial UCL tears, which make up about 60-70% of these injuries. If the hard-throwing right-hander can return to his old form he was a Cy Young Award candidate before his knee injury in August 2014 other pitchers in his situation are bound to at least consider the route he took.

I hope this opens another path for guys, Richards said. Obviously, if you can prevent being cut on and having surgery, thats the No. 1 priority. I hope guys dont just jump right into Tommy John, that they at least explore this option.

Autoplay

Show Thumbnails

Show Captions

Ageless veteran Bartolo Colon was the first pitcher widely known to have undergone stem cell therapy as he sought to recover from elbow and shoulder ailments in 2010. At the time, the ethics of the procedure were questioned, especially because the doctor who performed it, South Florida-based Joseph Purita, acknowledged using human growth hormone in previous treatments, though not in Colons.

Since then, the use of stem cells has become more mainstream. They are the focus of Yoons practice.

As more and more people start to use it, youre getting a better sense for what it can and cant do, Yoon said. Baseball definitely has opened up to it quite a bit, and as we see some of the successes like with Garrett, were getting a better understanding that theres a lot of potential here with these types of treatment.

Yoon calls stem cell therapy a super PRP because it combines the curative properties of that treatment with more healing agents, and said it can be used on tendon tears, muscle tears and strains and even to address degenerative joint disease.

However, much remains unknown about the benefits of stem cells. Lyle Cain, an orthopedist who has performed both Tommy John surgeries and stem cell treatments at the Andrews Sports Medicine & Orthopaedic Center in Birmingham, Ala., said most of the research has been anecdotal, not scientific.

We still dont have a good understanding even four or five years into it exactly what the stem cells do, what their method is, Cain said. The theory is theres probably a chemical reaction where it releases chemicals in the cell that help the healing process. The stem cells arent necessarily put in there with the thought theyre going to become ligament, but theres probably a cellular chemical mechanism that helps the healing response.

And as Heaney discovered, theyre not always effective. His tear was located farther down the arm, which reduced his chances of success with stem cell therapy. Richards was a better candidate because his injury, though deemed high grade, was located within the ligament, like a slit on a rubber band.

But because Heaney was looking at likely missing most or all of 2017 even if he had surgery right away, he decided to try stem cells. The timing of the injury plays a major role in whether pitchers contemplate alternatives to surgery, with the more conservative approach often recommended if it happens early in the season.

Heaney said he doesnt regret taking that route, and would have been upset if he had undergone the ligament-replacement operation right away, only to find out he could have returned to action quicker through another means.

Im glad it worked for him, he said of Richards. It would have been really awful if it hadnt worked for either of us. Then wed both look like idiots.

Their peers are paying attention. In a major league pitching community where about a quarter of its members have undergone Tommy John surgery, interest in the effectiveness of alternative cures is high.

The Los Angeles Dodgers Brandon McCarthy was not a candidate because his ligament tore clear off the bone, but said he had heard positive reports about stem cell treatment, not so much about PRP.

The Pittsburgh Pirates Daniel Hudson, a veteran of two Tommy Johns, is encouraged as well.

Its supposed to help repair the tissue. Before, ligaments just wont repair themselves, Hudson said. It might keep a lot of guys from going under the knife.

Thats Cains hope. He regularly treats UCL tears on high school, college and minor-league players with stem cells or PRP, but realizes theres heightened pressure on major leaguers to return to the field.

If more of them can do it without visiting an operating room, it would represent a major advancement for both the players and the industry.

I think overall the biologic treatment of these injuries will certainly progress and it will be somewhat the wave of the future, Cain said. There will be certain ligaments that are damaged enough that we dont have an answer; they have to reconstruct. But I think overall, if you look 15 years down the road, I suspect well be doing a lot more non-surgical treatment than surgical treatment.

Contributing: Gabe Lacques in Bradenton, Fla.

More here:
All eyes on Garrett Richards, in hopes stem cells stave off Tommy ... - USA TODAY

Poorly Jack Christmas, 8, needs 20k to get vital stem cell research – Hull Daily Mail

Comments(0)

A little boy with a rare genetic condition which left him unable to walk or talk could be one of just five people to contribute to vital research.

But Jack Christmas' family need to raise 20,000 to send the eight-year-old to America for the stem cell research in June.

Jack, of Gainford Grove, east Hull, was diagnosed with Mowat Wilson Syndrome in April 2012, and is one of only 171 children across the world to have the condition, caused by a gene deficiency or mutation.

Jack's mum, Dawn, said while the little boy is totally dependent on adults, he is making good progress.

"Jack doesn't talk, has to have all food pureed, can't feed or dress himself, is doubly incontinent, in fact he is totally dependent on adults," she said.

"All this said and done and he can now crawl, clap his hands and waves hello and goodbye as well as signing money and bird. Jack can also drink out of a feeder cup and on Christmas Eve 2015 Jack took his first unsteady independent steps."

More news: Maisie Rice, 9, needs life-changing operation so she play with her twin

As well as Mowat Wilson Syndrome, the Tweendykes School pupil has also been diagnosed with Global Development Delays, Gross Motor Disorder and Brain Atrophy. He also suffers from life-threatening seizures.

But now his family hope Jack can help doctors work towards finding a treatment for the condition by taking part in the research.

Dad Tony said: "For Jack, the gene that's affected is mutated, it is there, so there might be something doctors can do to manipulate it is.

"They might not be able to do anything and even if they can it might not be for 10 years, but Jack taking part in the research might help them find the answers.

"It also means if they do manage to find something, he will be able to have the treatment."

Tony said even if doctors were able to find a treatment, it probably wouldn't completely cure Jack's condition. He said: "He will always have Mowat Wilson Syndrome.

"But they might be able to find ways to make it easier for him."

The family have already raised 8,000 to fund the costs of travelling to the USA, but still need to raise 12,000 to foot the bill. And as part of their fundraising, they are hosting a fundraiser for the Life For A Kid Foundation a Hull charity supporting the family.

Dawn said the evening at Wawne Ferry pub, in Bransholme, would be a "night of singing, dancing, bingo, yes BINGO and a raffle."

Tickets for the 'Get ya dabbers ready' event, from 7.30pm on March 11, cost 5. You can also donate to Jack's cause on the family's Virgin Money Giving page.

More news: Courtroom disturbance halts sentencing of May Street murderer

Originally posted here:
Poorly Jack Christmas, 8, needs 20k to get vital stem cell research - Hull Daily Mail

Canadian Pacific makes a $1 million gift to fund stem cell research at the CHU Sainte-Justine – New hope for … – Canada NewsWire (press release)

From left to right: Dr. Fabrice Brunet, The Honorable Michael M Fortier, Mr. Keith Creel, President and CEO of Canadian Pacific, Dr. Gregor Andelfinger, Ms. Maud Cohen, Ms. Janice Pierson, Mr. Richard Lanoue, Mher Mike Stepanian, Samuel Gauthier, Mariama Hawa Barry, Samy Touati, Tyler Lanoue and Olivier Boissonneault. (CNW Group/CHU Sainte-Justine Foundation)

MONTRAL, Feb. 27, 2017 /CNW Telbec/ -An extraordinary $1 million commitment from Canadian Pacific (CP) towards stem cell research will allow the CHU Sainte-Justine to lead the way in developing new treatments to transform the lives of children suffering from complex congenital heart defects. Currently, there is no treatment available to provide a permanent means of repairing the heart. Today, patients and cardiac experts gathered to recognize the major impact of such strong support for research at the CHU Sainte-Justine, as well as the national importance of research in the development of innovative new stem cell technologies.

Thanks to this exceptional gift, CP is making possible the creation of Quebec's first platform for stem cell research and pediatric regenerative medicine. "These funds will allow us to purchase new equipment and recruit an additional researcher, which will significantly accelerate essential research, namely the identification of the mechanisms that form the heart and the types of intervention that can halt the progression of cardiac illnesses in children," stated Dr.Gregor Andelfinger, pediatric cardiologist at the CHU Sainte-Justine and associate research professor in the Department of Pediatrics at the Universit de Montral. "Our aim is to put in place biological factory, capable of producing cardiac tissues from stem cells," he added.

Research remains the best means of understanding, improving the treatment of, and curing congenital heart defects, which are the most commonly occurring birth defects in the world. They affect one in 80 children in Canada every year, many of whom eventually develop fatal heart failure.

"For over a decade, knowledge and understanding about heart defects have grown considerably at the CHU Sainte-Justine, along with the development of new tools for the genetic analysis of families where several family members suffer from a heart defect. Thanks to its team of experts specializing in pediatrics, cardiology, and congenital malformations, the CHU Sainte-Justine is a leader in providing better diagnoses and better targeted therapies to treat congenital heart defects," stated Mr. Fabrice Brunet, CEO of the CHUM-CHU Sainte-Justine.

Ms. Maud Cohen, CEO of the CHU Sainte-Justine Foundation, expressed gratitude for CP's generous support, which provides the hope of regenerating cardiac tissue in babies affected by congenital heart defects. "I am thrilled that the CHU Sainte-Justine is showing such leadership in pediatric regenerative medicine in Quebec, while also increasing our national and international outreach. The CHU Sainte-Justine Foundation is very proud to have the support of CP as a major donor to the Healing More Better campaign. Not only does this remarkable $1 million gift allow for the development of new cures to help save the lives of thousands of children suffering from cardiovascular diseases, but it will also serve as a driver for future funding. This support will enable Dr. Andelfinger's team to quickly undertake activities that show promising early results," she said.

"Since 2014, through our CP Has Heart program, we have been committed to making communities stronger and healthier thanks to research, treatment and prevention. With today's announcement, we have now donated nearly $10 million to this important cause" said Mr. Keith Creel, CP's President and CEO. "When we learned that the CHU Sainte-Justine was seeking to accelerate stem cell research, an extremely promising avenue for the repair of congenital heart defects, we immediately felt that it was an initiative we wanted to support. We firmly believe that a partnership with such a renowned institution as the CHU Sainte-Justine to create the first pediatric research platform in Quebec will significantly improve upon current treatments. This will ensure that the thousands of babies born with heart defects every year will have a chance to grow up with healthy hearts and live healthy lives," Mr. Creel concluded.

For CP, this generous support for stem cell research is a way to pursue its mission to improve heart health throughout North America, and is a natural fit with a cause so close to the company's heart.

The CHU Sainte-Justine Foundation is grateful for CP's invaluable contribution, which will allow the teams at the CHU Sainte-Justine to continue to heal more children, better.

About the CHU Sainte-Justine FoundationThe CHU Sainte-Justine Foundation's mission is to engage the community and support the CHU Sainte-Justine in its pursuit of excellence and its commitment to providing children and mothers with one of the highest levels of healthcare in the world, now and in the future. fondation-sainte-justine.org/en/

About the CHU Sainte-JustineThe Sainte-Justine university hospital centre (CHU Sainte-Justine) is the largest mother-child centre in Canada and the second largest pediatric hospital in North America. A member of the Universit de Montral extended network of excellence in health (RUIS), Sainte-Justine has 5,664 employees, including 1,578 nurses and nursing assistants; 1,117 other healthcare professionals; 502 physicians, dentists and pharmacists; 822 residents and over 200 researchers; 300 volunteers; and 3,400 interns and students in a wide range of disciplines. Sainte-Justine has 484 beds, including 35 at the Centre de radaptation Marie Enfant (CRME), the only exclusively pediatric rehabilitation centre in Quebec. The World Health Organization has recognized CHU Sainte-Justine as a "health promoting hospital." chusj.org

About Canadian PacificCanadian Pacific (TSX:CP)(NYSE: CP) is a transcontinental railway in Canada and the United States with direct links to eight major ports, including Vancouver and Montreal, providing North American customers a competitive rail service with access to key markets in every corner of the globe. CP is growing with its customers, offering a suite of freight transportation services, logistics solutions and supply chain expertise. Visit cpr.ca to see the rail advantages of CP.

About CP Has HeartAt CP, we know that a railroad may serve as the arteries of a nation, but at its heart is community. That's why, through CP Has Heart, we've already committed nearly $10 million to help improve the heart health of men, women and children across North America. And along the way, we're showing heart whenever we can. Find out more on http://www.cpr.ca or @CPhasHeart.

SOURCE CHU Sainte-Justine Foundation

For further information: CHU Sainte-Justine Foundation, Delphine Brodeur, Director, Communication, public relations and donor relations, 514 345-4931, ext. 4356, dbrodeur@fondationSainteJustine.org

View original post here:
Canadian Pacific makes a $1 million gift to fund stem cell research at the CHU Sainte-Justine - New hope for ... - Canada NewsWire (press release)

Stem cell therapy can help in treating diabetic heart disease – India.com

Karaikal, Feb 28 (PTI) Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge.

Patients suffering from the condition have to undergo lifelong treatment and medications. In this backdrop, advancements in stem cell therapy assume significance, he said.

This is published unedited from the PTI feed.

Antodaya, Humsafar Express to be launched today; Suresh Prabhu to unveil new catering policy for railways today

Uttar Pradesh Assembly elections 2017 LIVE: 57.36% voter turnout recorded till 5 PM in the fifth phase

Oscars 2017: Late Bollywood veteran Om Puri remembered at 89th Academy Awards!

Oscars 2017: Moonlight star Mahershala Ali is now best 'Actor in a Supporting Role'

Oscar Awards 2017 Live: When is Oscars 2017? Where to watch 89th Academy Awards LIVE Streaming & online telecast in India?

Here is the original post:
Stem cell therapy can help in treating diabetic heart disease - India.com